Literature DB >> 3140450

Pharmacokinetic study of orthoclone OKT3 serum levels during treatment of acute renal allograft rejection.

G Goldstein1, D J Norman, K R Henell, I L Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3140450     DOI： 10.1097/00007890-198810000-00025

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  7 in total

1.  Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.

Authors:  Sandrine Vessillier; Madeline Fort; Lynn O'Donnell; Heather Hinton; Kimberly Nadwodny; Joseph Piccotti; Peter Rigsby; Karin Staflin; Richard Stebbings; Divya Mekala; Aarron Willingham; Babette Wolf
Journal:  Cytokine X       Date:  2020-12

Review 2.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

Review 5.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients.

Authors:  P Brusa; R Casullo; F Dosio; L Cattel; S Beltramini; R Chiappetta; L Tosetti; E Andorno; M Salizzoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

7.  The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients.

Authors:  Daniel R Getts; William G Kramer; Alexander C Wiseman; Stuart M Flechner
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.